Active Ingredient(s): Loncastuximab Tesirine-lpyl
FDA Approved: * April 23, 2021
Pharm Company: * ADC Therapeutics SA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zynlonta Overview

Loncastuximab tesirine , sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma.[1] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.[1] Loncastuximab tesirine was approved for medical use in the United States in April 2021.[1][2] Contents 1 Medical uses 2 Technology 3 Clinical trials 4 Orphan drug designation 5 Ref...

Read more Zynlonta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Loncastuximab_tesirine

Recent Zynlonta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Loncastuximab Tesirine-lpyl
  • Injection: 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Loncastuximab Tesirine-lpyl or a similar ingredient: (1 result)